Market Overview

The global rotavirus prophylaxis market size accrued earnings worth approximately USD 8.15 Million in 2023 and is predicted to gain revenue of about USD 20.68 Million by 2032, is set to record a CAGR of nearly 10.9% over the period from 2024 to 2032.

The market of rotavirus prophylaxis finds a focus on preventing diseases caused by this virus which is one of the major diseases leading to severe diarrhoea and vomiting causing dehydration majorly in the infants. This virus is very contagious and profoundly leads to significant health complications such as hospitalization and death, mostly in regions with unavailability and less access to healthcare. This infection represents one of the major public health threats in low- and middle-income countries with failing infrastructures to meet such infections. The prevention measure taken in this market has been vaccination, which has reduced illness and mortality due to rotavirus.

The drivers of this market are rotavirus vaccines. Of the commercially available vaccines, these are Rotarix and RotaTeq, oral vaccines. These vaccines work by the activation of the immune system to elicit immunity against infection by the virus. Given over a course of injections shortly after birth, these vaccines have reduced the incidence of severe rotavirus infections, which are severe enough to require medical attention. These vaccines have also proven to be very effective in preventing hospitalizations and deaths, which has seen them included in the immunization programs of many countries, especially with the support of global health organizations such as WHO, Gavi the Vaccine Alliance, and UNICEF.

Market growth is supported by a growing awareness of rotavirus as one of the biggest health concerns, especially in children in developing countries. The governing bodies and international organization has focused efforts to expanding the access to vaccines that provide immunity against rotavirus infection through broader immunization campaigns. This is especially important where the burden of diseases due to rotavirus infection remains prevalent. The demand has increased further due to its inclusion in routine immunization programs as an effort to make vaccines accessible and affordable in resource-limited settings.

Other factors driving the market growth include advancements in vaccine technology. Specifically, heat-stable vaccines that do not need to be refrigerated provide a potential for far wider distribution and vaccination capacity compared to the traditional vaccines, easing the logistical problems associated with the delivery of their own.

Even though the market is expanding, challenges persist, such as vaccine hesitation in regions, inadequate health infrastructure in numerous areas, and high costs of the vaccines when financial aid or subsidies are not present. Efforts to bridge the mentioned gaps are currently underway with the assistance of health partnerships worldwide in extending vaccine access and coverage.

Rotavirus prophylaxis market is still in progress and, as of now, follows vaccination as the leading approach in fighting and controlling the disease. Growth, awareness, and access improvement mean that in the potential future, even in regions where rotavirus probably exerts its greatest impacts, the market is going to sustain its growth pattern.

Key Findings:

• Rotavirus Secular Trends in the United States Prevaccine era:
• Estimated 2.7 million cases per year
• 95% of children infected by 5 years of age
• Following the introduction of rotavirus vaccine:
• Annually averted:
• 280,000 clinic visits
• 62,000 emergency department visits
• 45,000 hospitalizations

Market Drivers

Increasing Awareness of Rotavirus and Its Impact

Rotavirus is a major cause of severe diarrhoea and dehydration in infants and young children, particularly in developing and more recently in middle-income countries. It's a major contributor to child hospitalization and death, especially in places where access to healthcare and access to clean water are limited. Ever increasing understanding of the burden of rotavirus has led to an enhanced demand for preventive measures mainly through vaccination.

Public health campaigns and education have been quite important in making people aware of the dangers that rotavirus brings. All these efforts are targeted at parents, caregivers, and healthcare providers to create awareness on the importance of vaccination in preventing severe illness and reducing childhood mortality, especially in countries where the burden of disease is high. Consequentially, more and more governments have been including rotavirus vaccines in their national immunization schedules; wider coverage of the vaccine has resulted in significantly reduced incidence of illness and deaths due to rotavirus in children.

Key findings

• Rotavirus is estimated to cause 37% of the total diarrheal deaths and 40% of the total diarrhea-related hospitalizations in children under five years of age worldwide.

Market Opportunities

Expansion in Emerging Markets

Due to lack of access to healthcare and vaccines, rotavirus has been the common cause of severe diarrhoea and death among infants and young children in most low- and middle-income countries. Regions generally suffer from serious health dilemmas in morbidity and mortality from the infection of rotavirus. However, governments and international organizations like WHO and Gavi, the Vaccine Alliance, are also increasing their investment in healthcare; this is a great opportunity to increase access and coverage of vaccines.

Through these partnerships, funding and logistical support, as well as technical know-how, facilitates the mass rollout of vaccination programs, particularly in regions like Africa, Asia, and Latin America, where the burden of rotavirus weighs more.

This is a great opportunity to increase access and coverage of vaccines. On the other hand, governments and international organizations like WHO and Gavi, the Vaccine Alliance, are also increasing their investment in healthcare. Expanded immunization programs would lead to a substantial reduction in the number of child deaths as these programs have been proven to significantly reduce severe cases of rotavirus infection. Of course, it would be among the long-term sustainable effects for both the reduction of the public health burden of the virus as well as the health outcome of children in such regions.

Market Restraining Factors

Vaccine Accessibility and Affordability

Financial cost indeed is one of the major obstacles to immunization efforts in low- and middle-income countries. In any healthcare budget-constrained setting, high vaccine costs may be unbearable, as it limits the extent to which governments can subsidize or distribute vaccines free to households. When funding and support from organizations such as Gavi and WHO are extended to the households, their pricing may still be unaffordable to low-income households.

This financial bar restriction limits the vaccination usage by many families, meaning less immunization of children to rotavirus, and thus exposing them to severe diarrhoea and other dehydration episodes caused by the rotavirus. In some instances, the parents may have other health care needs or expenditures that they may want to address, hence a very low vaccination uptake in those regions, implying an increased prevalence of severe rotavirus diarrhoea and possibly dehydration. Vaccine affordability must be addressed to create a better opportunity for accessible protection needed by vulnerable groups from diseases caused by the rotavirus.

Segmentation Analysis

The market scope is segmented because of by Vaccine Type, by Distribution Channel, by End-User.

By Vaccine Type

Based on the Vaccine Type of the market is segmented into Monovalent Vaccines, Pentavalent Vaccines.

The effects of RotaTeq are more evident in regions where diversity in rotavirus strains is higher, thus conferring wider immunity in populations. Monovalent vaccines, like the Rotarix vaccine, are manufactured to offer immunity to a specific rotavirus strain, which is most dominant and causes frequent sporadic cases of severe diarrhoea in children. Monovalent vaccines are highly effective in inhibiting infections by that serotype, and thus they have been utilized to a considerable extent in regions where a particular serotype predominates. For instance, Rotarix is added to the national immunization schedules in most countries, and it has been proven that its application decreases the incidence of rotavirus-associated diseases dramatically.

Another difference between the two vaccines is in broader coverage’s. Pentavalent vaccines such as RotaTeq are designed to protect against multiple strains of rotavirus in a child. This makes RotaTeq especially useful in settings where many strains of rotavirus are circulating and, therefore, provides more comprehensive immunity. Pentavalent vaccines will be able to decrease the occurrence of more severe cases and hospitalizations more effectively in areas with greater diversity of the viral strain by covering multiple strains of the virus at a time.

By Distribution Channel

Based on the Distribution Channel of the market is segmented into Government Programs, Private Clinics and Hospitals, Pharmacies and Drug Stores.

Pharmacies and drugstores retail vaccines over-the-counter, though less often. Even this channel is often comprised by the state and private health-care supply. Government programs are actually responsible for disseminating the rotavirus vaccines mainly in developing and middle-income countries through their schedules in national immunization programs. Such vaccines are provided free or at a discount price by public health care systems, which make them widely available, especially in the poor region with very little medical infrastructures. For example, in India, rotavirus vaccine is offered under the universal immunization program, which decreases diarrhoea-related child mortality significantly. Such programs have had a monopoly over vaccine distribution in low-income countries due to their accessibility and government-subsidized nature.

In the wealthier regions, private clinics and hospitals also administer vaccines. Hence, families will be able to source vaccines from private providers of health care. This would be a major sector in developed economies where the healthcare delivery system is more private. Many families in the United States, for instance, go for vaccinations of their children at private paediatric clinics.

Regional Snapshots

By region, Insights into the markets in North America, Europe, Asia-Pacific, Latin America and MEA are provided by the study. North America, and specifically the United States, has a very developed health care delivery system with unlimited access to vaccines. Routine immunization timetables consist of rotavirus vaccines, which have reached high coverage rates thanks to the strength of government programs and private health care providers. Advanced health care infrastructure exists as well as knowledge of the way childhood vaccinations play a vital role. All babies are vaccinated with rotavirus, according to the U.S. Centres for Disease Control and Prevention, which has already resulted in great declines in hospitalizations and deaths related to rotavirus; leadership in North America is driven by high adoption levels, government support, and strong healthcare systems.

The landscape of Europe is on par because most of the countries have incorporated rotavirus vaccines into their national immunization programs. In fact, countries such as Germany, the UK, and France have achieved high vaccination rates due to the well-endowed health systems coordinated by the government. Furthermore, the type of advanced health infrastructure plus the increasing consciousness of rotavirus prevention affect the European market. Yet, the vaccination coverage is differed within the European countries depending upon government policies as well as public health priorities. Infections from rotavirus have dramatically decreased in countries like the UK, where it has been introduced, and the growth in this region is quite significant.

One of the most fastest-growing markets for rotavirus prophylaxis is the Asia-Pacific region. Market growth will be contributed by countries such as India, China, and Japan. In India, the government has introduced vaccination against rotavirus under the Universal Immunization Program that decreases child mortality from diarrhoea effectively. Nevertheless, the coverage rates remain different between regions, and the accessibility of vaccines in rural areas is another problem. Market growth in this region will probably be fuelled by the emerging government initiatives and expanding investments in healthcare from China. This region will be an important market for rotavirus prophylaxis due to the high birth rates and large paediatric population in Asia-Pacific.

Latin America is another major region, where countries like Brazil and Mexico have introduced countrywide rotavirus immunization programs. This has been instrumental in reducing the hospital and death due to rotavirus by a great extent. Immunizations for low-income areas have further gained momentum with support from international organizations such as Gavi, significantly increasing vaccinations and helping grow the market in the region.

The weak health infrastructure coupled with a wide prevalence of rotavirus infections creates an enormous challenge for the Middle East & Africa, though international organizations such as the WHO and Gavi are instrumental in supplementing vaccination programs. Countries such as South Africa, with government-coordinated immunization efforts, have witnessed considerable improvements in child healthcare. Still, under-vaccinated areas of Africa pose both challenges and opportunities to this market.

The rotavirus prophylaxis market is, thus, driven by differences in the healthcare infrastructure and government policies across the globe, along with public awareness of the disease and the vaccines. Advanced regions like North America and Europe lead the industry due to high, well-developed healthcare infrastructures and high vaccination rates. Markets, however, are growing in Asia-Pacific, Latin America, and Africa regions due to efforts put in place by governments and international agencies to increase vaccine access.

List of Companies Profiled

• Lanzhou Institute of Biologicals Products Co. Ltd
• QIMR Berghofer Medical Research Institute
• BIOVIRx Inc
• Serum Institute of India Pvt. Ltd.
• Merck & Co. Inc.
• Bharat Biotech
• GlaxoSmithKline plc
• Sanofi and Others.

Key Industry Developments

• In December 2023, in order to speed possible novel treatments for cancer and chronic inflammation, QIMR Berghofer is collaborating with Syntekabio, a Korean firm, to use its cutting-edge artificial intelligence (AI) and high-performance computing.
• In May 2024, in order to promote Needle-Free Injection System technology, Serum Institute of India (SII), the biggest vaccine maker in the world, has made a strategic investment in IntegriMedical, purchasing a 20% share in the business.

Report Coverage

The report will cover the qualitative and quantitative data on the Global Rotavirus Prophylaxis Market. The qualitative data includes latest trends, market players analysis, market drivers, market opportunity, and many others. Also, the report quantitative data includes market size for every region, country, and segments according to your requirements. We can also provide customize report in every industry vertical.

Report Scope and Segmentations

Regional Analysis

North America accounted for the highest xx% market share in terms of revenue in the Rotavirus Prophylaxis market and is expected to expand at a CAGR of xx% during the forecast period. This growth can be attributed to the growing adoption of Rotavirus Prophylaxis. The market in APAC is expected to witness significant growth and is expected to register a CAGR of xx% over upcoming years, because of the presence of key Rotavirus Prophylaxis companies in economies such as Japan and China.

The objective of the report is to present comprehensive analysis of Global Rotavirus Prophylaxis Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language.

Rotavirus Prophylaxis Market Report is also available for below Regions and Country Please Ask for that

North America

• U.S
• Canada

Europe

• Switzerland
• Belgium
• Germany
• France
• U.K
• Italy
• Spain
• Sweden
• Netherland
• Turkey
• Rest of Europe

Asia-Pacific

• India
• Australia
• Philippines
• Singapore
• South Korea
• Japan
• China
• Malaysia
• Thailand
• Indonesia
• Rest Of APAC

Latin America

• Mexico
• Argentina
• Peru
• Colombia
• Brazil
• Rest of South America

Middle East and Africa

• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest Of MEA

Points Covered in the Report

• The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.
• The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analysed 5 years data history and forecast.
• The growth factors of the market are discussed in detail wherein the different end users of the market are explained in detail.
• Data and information by market player, by region, by type, by application and etc., and custom research can be added according to specific requirements.
• The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Key Questions:

• How much the global Rotavirus Prophylaxis Market valued?
• Which region has the largest share in 2024 for the global Rotavirus Prophylaxis Market?
• What are the driving factors for the market?
• Which is the leading segment in the global market?
• What are the major players in the market?

Research Scope of the Market

• Historic year: 2019-2022
• Base year: 2023
• Forecast: 2024 to 2032
• Representation of Market revenue in USD Million

Rotavirus Prophylaxis Market Trends: Market key trends which include Increased Competition and Continuous Innovations Trends: